Pancreatic Cancer Research

ResearcherUniversity of MinnesotaActive in the last 2 years

Shuhei Shinoda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4128-2177; OpenAlex author ID A5069138825. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. A Novel Index Consisting of Age, CA19-9, and Methylated Somatostatin Is Useful for Diagnosing Early Pancreatic Cancer. Co-author DOI 10.1002/cam4.72202↗
  2. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. First author DOI 10.1038/s41598-026-56838-2↗
  3. Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis. Co-author DOI 10.1038/s41598-025-11271-9↗
  4. Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Co-author DOI 10.1111/cas.15903↗
  5. Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11091-y↗
  6. Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-023-11677-6↗
  7. Fatty acid binding protein 4 regulates pancreatic cancer cell proliferation via activation of nuclear factor E2-related factor 2. First author DOI 10.1016/j.soard.2021.12.002↗
  8. Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery. Co-author DOI 10.3390/biomedicines10061284↗
  9. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Co-author DOI 10.1186/s12885-020-07167-8↗
  10. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Co-author DOI 10.18632/oncotarget.25421↗
  11. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. Co-author DOI 10.21873/invivo.11286↗
  12. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. Co-author DOI 10.1186/s12885-016-2744-9↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Takami · 7 shared papers, 2016–2026 · strength 1.15
  2. Masato Yamamoto · 5 shared papers, 2022–2026 · strength 1.10
  3. Takahiro Yamasaki · 6 shared papers, 2016–2026 · strength 0.86
  4. Isao Sakaida · 6 shared papers, 2016–2023 · strength 0.69
  5. Shigeyuki Suenaga · 3 shared papers, 2018–2026 · strength 0.64
  6. Shogo Amano · 5 shared papers, 2018–2023 · strength 0.63
  7. Mizuho Sato‐Dahlman · 3 shared papers, 2022–2025 · strength 0.62
  8. Hirofumi Harima · 5 shared papers, 2016–2023 · strength 0.60
  9. Kaori Hamamoto · 2 shared papers, 2026 · strength 0.55
  10. Kazuho Inoko · 2 shared papers, 2023–2025 · strength 0.45
  11. Shin Hamada · 1 shared paper, 2026 · strength 0.29
  12. Atsushi Masamune · 1 shared paper, 2026 · strength 0.29
  13. Shoko Tabara · 1 shared paper, 2026 · strength 0.26
  14. Yutaka Suehiro · 1 shared paper, 2026 · strength 0.26
  15. Julia Davydova · 1 shared paper, 2023 · strength 0.19
  16. Nikita Sharma · 1 shared paper, 2023 · strength 0.19
  17. Brett Roach · 1 shared paper, 2022 · strength 0.19
  18. Keith M. Wirth · 1 shared paper, 2022 · strength 0.17
  19. Manabu Sen-yo · 1 shared paper, 2018 · strength 0.09
  20. Michitaka Kawano · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.